Elcode Smart, active and transdermal patch for the ADMINISTRATION OF DRUGS.
Elcode ELCODE:
ELCODE patch is a disposable system for transdermal delivery and controlled release of active substances.
What is it?
Product Differentiation
ELCODE is a system for the transdermal administration of high added-value active substances using a smart active patch. It may have multiple applications for different types of drugs already on the market.
ELCODE has significant advantages over current systems: Small device. Non-invasive. Easy placement and handling. Flexible and light to adapt to the human body. Low-cost system. Minimises the appearance of erythema due to the electric current. Controlled drug release.
How does it work? Electrical stimuli and hydrogel technology are combined in order to achieve the local and systemic delivery of drugs with restricted forms of administration which were previously ineffective percutaneously.
Measured dosage. May be systemic or local depending on the programming conditions of the system. For domestic or hospital use. Includes preview software aimed at predicting drug administration in the right place and time. Its advanced platform, designed to generate iontophoretic stimuli in DC or in pulse mode, uses voltage as well as power control.
Asset Situation TRL1 TRL2 TRL3 TRL4 TRL5 TRL6
The transdermal patch prototype is now fully developed and the active transport of drugs has been confirmed, with three proof-of-concepts including: an anti-inflammatory and immunodepressant, an analgesic, an antipyretic and an antiviral.
Application Diagnosis of allergens: to increase accuracy, sensitivity and patient comfort while reducing the assessment.
A porcine skin model has been developed (in vitro test) to test the aforementioned drugs.
Immunisation and vaccination: as well as avoiding the need for hypodermic needles, administration of the vaccine could improve immune response due to the orientation of the immunogenic cells in the skin.
A patent has been registered to protect different applications and electrode models. EP14382362.3
Treatment of perimenopausal symptoms and osteoporosis: some therapeutic agents show metabolising problems in the gastrointestinal tract and liver due to the use of injections.
Elcode
Delivery and release of hyaluronic acid.
TECNALIA TECNALIA is the first privately funded applied research centre in Spain and one of the leading such centres in Europe. With a workforce of more than 1,400 highly qualified people, a 110 million Euros turnover and a portfolio with over 4,000 clients, TECNALIA focuses its activity towards transforming knowledge into GDP to improve people’s quality of life, by creating business opportunities for companies.
IDEAS THAT CREATE VALUE
“TECNALIA transforms knowledge into GDP to improve People’s quality of life by generating business opportunities for Companies”
Inspiring Business
ONE HUNDRED AND TEN
03.
04.
05.
HEALTH
INNOVATION STRATEGIES
INDUSTRY AND TRANSPORT
ICT-EUROPEAN SOFTWARE INSTITUTE
ENERGY AND ENVIRONEMENT
SUSTAINABLE CONSTRUCTION
02.
06.
: Garbiñe Atorrasagasti . garbine.atorrasagasti@tecnalia.com Goran Bijelic . goran.bijelic@tecnalia.com
+ info
+ 4,000 CLIENTS WITH 7 BUSINESS DIVISIONS AT THEIR SERVICE
Elcode
TECHNOLOGICAL SERVICES
EXPERTS ON STAFF
MILLION EUROS INCOME
01.
1 +1,400 +4,000 st
FIRST SPANISH PRIVATE ORGANISATION IN FINANCIAL RETURN, PROJECTS APPROVED AND LED WITHIN THE EC 7FP
07.